Herzberg Jonas, Fischer Bastian, Becher Heiko, Becker Ann-Kristin, Honarpisheh Human, Guraya Salman Yousuf, Strate Tim, Knabbe Cornelius
Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, 21465 Reinbek, Germany.
Institut für Laboratoriums-und Transfusionsmedizin, Herz-und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germany.
Vaccines (Basel). 2022 May 20;10(5):805. doi: 10.3390/vaccines10050805.
Little is known about the longevity of antibodies after a third dose of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (BioNTech/Pfizer, Mainz, Germany). Therefore, serum antibody levels were evaluated after a third dose of BNT162b2 in healthy adult healthcare workers in Germany. These antibody levels dropped significantly within a short period of 11 weeks from 4155.59 ± 2373.65 BAU/mL to 2389.10 ± 1433.90 BAU/mL, p-value < 0.001 but remained higher than after the second dose (611.92 ± 450.31 BAU/mL). To evaluate the quality of the humoral immune response, we additionally measured neutralizing antibodies, which also showed a small but significant decrease within this short period. These data underline the positive effect of a third dose of BNT162b2 concerning antibody re-induction but also shows a drop of Anti-SARS-CoV-2-IgG within a short span of time.
关于基于mRNA的SARS-CoV-2疫苗BNT162b2（德国美因茨BioNTech/辉瑞公司）第三剂接种后抗体的持久性，人们了解甚少。因此，对德国健康成年医护人员接种第三剂BNT162b2后的血清抗体水平进行了评估。这些抗体水平在短短11周内从4155.59±2373.65 BAU/mL显著降至2389.10±1433.90 BAU/mL，p值<0.001，但仍高于第二剂接种后（611.92±450.31 BAU/mL）。为了评估体液免疫反应的质量，我们还检测了中和抗体，其在这段短时间内也出现了小幅但显著的下降。这些数据强调了第三剂BNT162b2在抗体再诱导方面的积极作用，但也显示出抗SARS-CoV-2-IgG在短时间内有所下降。
